We are live on ! Find out more
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings

177 hedge funds and large institutions have $3.36B invested in Mirati Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 68 increasing their positions, 57 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more call options, than puts

Call options by funds: $221M | Put options by funds: $159M

21% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 24

19% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 57

3% more funds holding

Funds holding: 172 → 177 (+5)

25% less capital invested

Capital invested by funds: $4.48B → $3.36B (-$1.12B)

54% less funds holding in top 10

Funds holding in top 10: 13 → 6 (-7)

Holders
177
Holders Change
+5
Holders Change %
+2.91%
% of All Funds
3.88%
Holding in Top 10
6
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-53.85%
% of All Funds
0.13%
New
29
Increased
68
Reduced
57
Closed
24
Calls
$221M
Puts
$159M
Net Calls
+$61.5M
Net Calls Change
-$44.3M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$50.2M
2
CAM
Cormorant Asset Management
Massachusetts
+$46.9M
3
PHS
PFM Health Sciences
California
+$40.5M
4
PA
Perceptive Advisors
New York
+$38.9M
5
RI
RTW Investments
New York
+$31.7M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$113M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$69.4M
3
FCM
Farallon Capital Management
California
-$65.2M
4
EC
EcoR1 Capital
California
-$51.9M
5
VC
Vivo Capital
California
-$24M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
151
Tower Research Capital (TRC)
New York
$112K +$135K +1,438 New
Zurich Cantonal Bank
152
Zurich Cantonal Bank
Switzerland
$111K – – –
QI
153
QS Investors
New York
$102K +$122K +1,300 New
FMT
154
First Mercantile Trust
Tennessee
$91K +$28.2K +301 +35%
Rockefeller Capital Management
155
Rockefeller Capital Management
New York
$90K +$108K +1,153 New
SCM
156
Sarissa Capital Management
Connecticut
$77K – – –
SGAM
157
Smith Group Asset Management
Texas
$74K +$89.2K +950 New
AA
158
AlphaMark Advisors
Kentucky
$31K – – –
GHCM
159
Glen Harbor Capital Management
California
$29K – – –
MAM
160
Meeder Asset Management
Ohio
$26K -$110K -1,167 -78%
MCIM
161
Meadow Creek Investment Management
Georgia
$24K – – –
QT
162
Quantbot Technologies
New York
$23K -$9.38K -100 -25%
CSS
163
Cubist Systematic Strategies
Connecticut
$22K -$1.95M -20,781 -99%
LTFS
164
Ladenburg Thalmann Financial Services
Florida
$22K – – –
EP
165
Elkfork Partners
Oregon
$19K – – –
Daiwa Securities Group
166
Daiwa Securities Group
Japan
$19K +$2.44K +26 +12%
EWA
167
Evolution Wealth Advisors
Florida
$17K +$2.16K +23 +11%
TAM
168
Tyers Asset Management
Texas
$14K – – –
Nisa Investment Advisors
169
Nisa Investment Advisors
Missouri
$12K – – –
PHK
170
Point72 Hong Kong
Hong Kong
$11K +$13.7K +146 New
QT
171
Quantamental Technologies
New York
$7K -$45.3K -483 -84%
US Bancorp
172
US Bancorp
Minnesota
$4K -$16.1K -172 -77%
Fifth Third Bancorp
173
Fifth Third Bancorp
Ohio
$4K +$4.69K +50 New
FDCDDQ
174
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3.12K – – –
GT
175
Glenmede Trust
Pennsylvania
$5 -$134K -1,425 -95%
4 5 6
7
8

MRTX Hedge Fund Activity: Q3 2019 in Review

177 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2019, worth a combined $3.36B — down 25% from $4.48B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new MRTX positions and 24 closed out — a net gain of 5 holders — while 68 added to existing stakes and 57 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $50.2M. The largest seller was Baker Bros. Advisors, cutting an estimated $113M.

  • 177 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2019, up from 172 in Q2 2019.
  • Funds reported $3.36B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2019, down 25% quarter-over-quarter.
  • 29 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2019 and 24 closed out, a net change of +5 holders.
  • The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2019 was OrbiMed, an estimated $50.2M added.
  • The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2019 was Baker Bros. Advisors, an estimated $113M sold.

Based on aggregated 13F filings for Q3 2019.